GW Pharma presents more data on anti-seizure effects of Epidiolex

28 August 2018

UK-based cannabis specialist GW Pharmaceuticals (Nasdaq: GWPH) is presenting data on the safety and efficacy of its CBD oral solution at the Annual European Congress of Epileptology, currently underway in Vienna.

Following its recent landmark US approval of Epidiolex (cannabidiol) for the treatment of seizures associated with rare epilepsies, the firm is awaiting a review from the Drug Enforcement Administration (DEA) to rule on its potential for abuse.

The studies also include data related to the pharmacology of CBD, and its antiseizure properties, which the firm says will provide additional understanding of CBD’s role in the management of such diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK